Long term outcome of anastomotic leakage in patients undergoing low anterior resection for rectal cancer.


Journal

BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800

Informations de publication

Date de publication:
20 Aug 2020
Historique:
received: 17 07 2019
accepted: 23 06 2020
entrez: 22 8 2020
pubmed: 21 8 2020
medline: 15 4 2021
Statut: epublish

Résumé

The influence of anastomotic leakage (AL) on local recurrence rates and survival in rectal cancer remains controversial. The aim of this study was to analyze the effect of asymptomatic anastomotic leakage (AAL) and symptomatic anastomotic leakage (SAL) on short- and long-term outcome after curative rectal cancer resection. All patients who underwent surgical resection of non-metastatic rectal cancer with curative intent from January 2005 to December 2017 were retrospectively analyzed. Short-term morbidity, long-term functional and oncological outcomes were compared between patients with SAL, AAL and without AL (WAL). Overall, 200 patients were included and AL was observed in 39 (19.5%) patients (10 AAL and 29 SAL) with a median follow-up of 38.5 months. Rectal cancer location and preoperative neoadjuvant treatment was similar between the three groups. Postoperative 30-day mortality rate was nil. The permanent stoma rate was higher in patients with SAL or AAL compared to WAL patients (44.8 and 30% vs 9.3%, p < 0.001). The mean wexner continence grading scale was significantly different between AAL (11,4 ± 3,8), SAL (10,3 ± 0,6) and WAL (6,4 ± 4,7) groups (p = 0.049). The 3 and 5-year overall and disease-free survival rates were similar between the 3 groups (86.6% /84% vs 100%/100% vs 76%/70 and 82.9%/77% vs 100%/100% vs 94.7%/88.3% for patients with SAL, AAL, and WAL, p = 0.480 and p = 0.527). The permanent stoma rate was significant higher in patients with SAL or AAL compared to WAL patients. AL did not impair long-term oncological outcome.

Sections du résumé

BACKGROUND BACKGROUND
The influence of anastomotic leakage (AL) on local recurrence rates and survival in rectal cancer remains controversial. The aim of this study was to analyze the effect of asymptomatic anastomotic leakage (AAL) and symptomatic anastomotic leakage (SAL) on short- and long-term outcome after curative rectal cancer resection.
METHODS METHODS
All patients who underwent surgical resection of non-metastatic rectal cancer with curative intent from January 2005 to December 2017 were retrospectively analyzed. Short-term morbidity, long-term functional and oncological outcomes were compared between patients with SAL, AAL and without AL (WAL).
RESULTS RESULTS
Overall, 200 patients were included and AL was observed in 39 (19.5%) patients (10 AAL and 29 SAL) with a median follow-up of 38.5 months. Rectal cancer location and preoperative neoadjuvant treatment was similar between the three groups. Postoperative 30-day mortality rate was nil. The permanent stoma rate was higher in patients with SAL or AAL compared to WAL patients (44.8 and 30% vs 9.3%, p < 0.001). The mean wexner continence grading scale was significantly different between AAL (11,4 ± 3,8), SAL (10,3 ± 0,6) and WAL (6,4 ± 4,7) groups (p = 0.049). The 3 and 5-year overall and disease-free survival rates were similar between the 3 groups (86.6% /84% vs 100%/100% vs 76%/70 and 82.9%/77% vs 100%/100% vs 94.7%/88.3% for patients with SAL, AAL, and WAL, p = 0.480 and p = 0.527).
CONCLUSION CONCLUSIONS
The permanent stoma rate was significant higher in patients with SAL or AAL compared to WAL patients. AL did not impair long-term oncological outcome.

Identifiants

pubmed: 32819329
doi: 10.1186/s12885-020-07109-4
pii: 10.1186/s12885-020-07109-4
pmc: PMC7439541
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

780

Références

Br J Surg. 2009 Sep;96(9):1066-75
pubmed: 19672927
Dis Colon Rectum. 2017 Aug;60(8):761-784
pubmed: 28682962
Colorectal Dis. 2011 Jun;13(6):632-7
pubmed: 20236150
World J Surg. 2017 Jan;41(1):277-284
pubmed: 27743072
Health Policy. 1996 Jul;37(1):53-72
pubmed: 10158943
Ann Surg. 2004 Aug;240(2):205-13
pubmed: 15273542
Cochrane Database Syst Rev. 2009 Jan 21;(1):CD006041
pubmed: 19160264
Br J Surg. 2005 Feb;92(2):211-6
pubmed: 15584062
Surgery. 2010 Mar;147(3):339-51
pubmed: 20004450
Arch Pathol Lab Med. 2009 Oct;133(10):1539-51
pubmed: 19792043
Br J Surg. 2005 Feb;92(2):225-9
pubmed: 15609382
N Engl J Med. 2004 Oct 21;351(17):1731-40
pubmed: 15496622
BMC Cancer. 2013 Sep 12;13:417
pubmed: 24028546
Ann Surg. 2005 Mar;241(3):465-9
pubmed: 15729069
BMJ. 1993 May 29;306(6890):1437-40
pubmed: 8518639
Ann Oncol. 2013 Oct;24 Suppl 6:vi81-8
pubmed: 24078665
Gastroenterol Clin Biol. 2004 Jun-Jul;28(6-7 Pt 1):562-8
pubmed: 15243389
Colorectal Dis. 2004 Nov;6(6):462-9
pubmed: 15521937
BMC Cancer. 2018 Oct 22;18(1):1022
pubmed: 30348115
Dis Colon Rectum. 2013 Mar;56(3):275-80
pubmed: 23392139
Dis Colon Rectum. 2015 Jul;58(7):637-44
pubmed: 26200677
Ann Surg. 2011 May;253(5):890-9
pubmed: 21394013
Ann Intern Med. 2007 Oct 16;147(8):573-7
pubmed: 17938396
Ann Surg. 2007 Aug;246(2):207-14
pubmed: 17667498
Br J Surg. 2015 Mar;102(4):416-22
pubmed: 25619499
Br J Surg. 2001 Mar;88(3):400-4
pubmed: 11260107
Gut. 1999 Mar;44(3):407-12
pubmed: 10026329
N Engl J Med. 2006 Sep 14;355(11):1114-23
pubmed: 16971718
Ann Surg. 2010 Nov;252(5):863-8
pubmed: 21037443
Surgery. 2017 Apr;161(4):1028-1039
pubmed: 27894710
World J Surg. 2017 Nov;41(11):2912-2922
pubmed: 28620675
Br J Surg. 2017 Feb;104(3):288-295
pubmed: 27762432
Dis Colon Rectum. 2009 Jul;52(7):1251-8
pubmed: 19571701
Dis Colon Rectum. 2006 Oct;49(10):1611-9
pubmed: 16990979
Colorectal Dis. 2017 Dec;19(12):1067-1075
pubmed: 28612478
Br J Surg. 1982 Oct;69(10):613-6
pubmed: 6751457
Ann Surg. 2005 Jan;241(1):9-13
pubmed: 15621985
Br J Surg. 1998 Mar;85(3):355-8
pubmed: 9529492
Ann Surg. 2012 May;255(5):922-8
pubmed: 22504191
Br J Surg. 2015 Apr;102(5):462-79
pubmed: 25703524
Int J Impot Res. 1999 Dec;11(6):319-26
pubmed: 10637462
N Engl J Med. 2001 Aug 30;345(9):638-46
pubmed: 11547717
Dis Colon Rectum. 2007 Feb;50(2):147-55
pubmed: 17160572
Br J Surg. 2010 Aug;97(8):1295-303
pubmed: 20602501
Dis Colon Rectum. 2016 May;59(5):369-76
pubmed: 27050598

Auteurs

Alice Artus (A)

Department of Digestive, Oncological, Endocrine, Hepato-Biliary, Pancreatic and Liver Transplant Surgery, Trousseau Hospital, Chambray les Tours, Avenue de la République, Chambray les Tours, France.

Nicolas Tabchouri (N)

Department of Digestive, Oncological, Endocrine, Hepato-Biliary, Pancreatic and Liver Transplant Surgery, Trousseau Hospital, Chambray les Tours, Avenue de la République, Chambray les Tours, France.

Othman Iskander (O)

Department of Digestive, Oncological, Endocrine, Hepato-Biliary, Pancreatic and Liver Transplant Surgery, Trousseau Hospital, Chambray les Tours, Avenue de la République, Chambray les Tours, France.

Nicolas Michot (N)

Department of Digestive, Oncological, Endocrine, Hepato-Biliary, Pancreatic and Liver Transplant Surgery, Trousseau Hospital, Chambray les Tours, Avenue de la République, Chambray les Tours, France.

Olivier Muller (O)

Department of Digestive, Oncological, Endocrine, Hepato-Biliary, Pancreatic and Liver Transplant Surgery, Trousseau Hospital, Chambray les Tours, Avenue de la République, Chambray les Tours, France.

Urs Giger-Pabst (U)

Department of General-, Visceral- and Transplant Surgery, University of Münster, Münster, Germany.

Pascal Bourlier (P)

Department of Digestive, Oncological, Endocrine, Hepato-Biliary, Pancreatic and Liver Transplant Surgery, Trousseau Hospital, Chambray les Tours, Avenue de la République, Chambray les Tours, France.

Céline Bourbao-Tournois (C)

Department of Digestive, Oncological, Endocrine, Hepato-Biliary, Pancreatic and Liver Transplant Surgery, Trousseau Hospital, Chambray les Tours, Avenue de la République, Chambray les Tours, France.

Aurore Kraemer-Bucur (A)

Department of Digestive, Oncological, Endocrine, Hepato-Biliary, Pancreatic and Liver Transplant Surgery, Trousseau Hospital, Chambray les Tours, Avenue de la République, Chambray les Tours, France.

Thierry Lecomte (T)

Department of Hepatogastroenterology and Digestive Oncology, Tours, France.

Ephrem Salamé (E)

Department of Digestive, Oncological, Endocrine, Hepato-Biliary, Pancreatic and Liver Transplant Surgery, Trousseau Hospital, Chambray les Tours, Avenue de la République, Chambray les Tours, France.

Mehdi Ouaissi (M)

Department of Digestive, Oncological, Endocrine, Hepato-Biliary, Pancreatic and Liver Transplant Surgery, Trousseau Hospital, Chambray les Tours, Avenue de la République, Chambray les Tours, France. m.ouaissi@chu-tours.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH